The nation of Zimbabwe has declined a major US healthcare agreement worth $367m (272 million pounds) spanning five years over Washington's demand for confidential data.
This move became public after a government memo from December was leaked, revealing that President Emmerson Mnangagwa believed the agreement was "unbalanced".
An official spokesperson later explained that the United States was demanding access to biological samples for scientific study and commercial purposes but was not willing to share the benefits from any future vaccines.
"We are forced to start the difficult and regrettable process of scaling back our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had furnished more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged further negotiations to reach a deal acceptable to both sides so the nation's critical HIV treatment initiative can continue.
Broader Context
This rejection follows a similar situation in Kenya, where a high court blocked a related health funding agreement after concerns were raised about the safety of citizens' health data.
Since resuming office recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had overseen assistance for the American government, but Trump argued its expenditure was "wasteful" and his government was pursuing direct bilateral agreements to enhance openness and accountability.
Based on statements, Sixteen African countries have to date signed similar health pacts, representing over $18.3bn of fresh investment.
Details of the Rejected Agreement
The money for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership could have provided significant advantages for Zimbabwean communities, particularly the 1.2 million currently receiving HIV treatment through American-funded initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"Our nation was requested to share its biological resources and data indefinitely, with no equivalent assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"Effectively, our country would provide the raw materials for medical research with no assurance that the end products would be available to our citizens if a new pandemic emerge."
Sovereignty and International Frameworks
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending systems previously set up via the international organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing system created to manage future global health emergencies.
"This mechanism is intended to ensure that when a nation provides its data, the benefits – such as vaccines and treatments – are distributed fairly, not commercialised exclusively by those with the capability to develop them."
The government's concerns regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We welcome continued dialogue with our American counterparts on how subsequent collaboration could be designed in a manner that respects the sovereignty and interests of each country."
Medical Community Response
Medical experts said it acknowledged the official position, but urged that negotiations must proceed since a large portion of the nation's Aids initiatives depended on international support.
"If specific concerns exist, such as those involving data governance or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," it added.
The situation underscores the complex challenges between accepting crucial foreign assistance and protecting local interests in an increasingly data-driven world.